Biopsy follow-up of prostate-specific antigen tests

American Journal of Preventive Medicine

Volumn 42, Issue 1, 2012, Pages 37-43

  Zeliadt, Steven B ^a,b,c   Buist, Diana S M ^b   Reid, Robert J ^b,d   Grossman, David C ^a,b,d   Ma, Jian ^d   Etzioni, Ruth ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL PRACTICE; FOLLOW UP; HEALTH CARE PLANNING; HUMAN; MALE; PROSTATE BIOPSY; UROLOGY; VELOCITY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; WASHINGTON;

EID: 83755205275     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2011.08.024     Document Type: Article

References (38)

1. A.B. Mariotto, R. Etzioni, M. Krapcho, E.J. Feuer Reconstructing PSA testing patterns between black and white men in the U.S. from Medicare claims and the National Health Interview Survey Cancer 109 9 2007 1877 1886 (Pubitemid 46668554)
2. P.H. Gann, C.H. Hennekens, M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 4 1995 289 294
3. C. Mettlin, P.J. Littrup, R.A. Kane Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change Data from the American Cancer Society National Prostate Cancer Detection Project Cancer 74 5 1994 1615 1620 (Pubitemid 24302984)
4. T. Stamey, N. Yang, A. Hay, J. McNeal, F. Freiha, E. Redwine Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916 (Pubitemid 17147932)
5. W.J. Catalona, J.P. Richie, F.R. Ahmann Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men J Urol 151 5 1994 1283 1290 (Pubitemid 24121936)
6. H.B. Carter, C.H. Morrell, J.D. Pearson Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease Cancer Res 52 12 1992 3323 3328
7. J.E. Oesterling, S.J. Jacobsen, C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men Establishment of age-specific reference ranges JAMA 270 7 1993 860 864 (Pubitemid 23234116)
8. I.M. Thompson, D.P. Ankerst, C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 1 2005 66 70 (Pubitemid 41002840)
9. W.J. Catalona, C.G. Ramos, G.F. Carvalhal, Y. Yan Lowering PSA cutoffs to enhance detection of curable prostate cancer Urology 55 6 2000 791 795 (Pubitemid 30330772)
10. I.M. Thompson, D.P. Ankerst, R. Etzioni, T. Wang It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer J Urol 180 4 2008 1219 1222
11. K. Lin, R. Lipsitz, T. Miller, S. Janakiraman Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force Ann Intern Med 149 3 2008 192 199
12. M.H. Kawachi, R.R. Bahnson, M. Barry NCCN clinical practice guidelines in oncology: prostate cancer early detection J Natl Compr Canc Netw 8 2 2010 240 262
13. K.L. Greene, P.C. Albertsen, R.J. Babaian Prostate specific antigen best practice statement: 2009 update J Urol 182 5 2009 2232 2241
14. F.H. Schroder, J. Hugosson, M.J. Roobol ERSPC Investigators Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 13 2009 1320 1328
15. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd PLCO Project Team Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 13 2009 1310 1319
16. H.L. Kim, D.A. Benson, S.D. Stern, G.S. Gerber Practice trends in the management of prostate disease by family practice physicians and general internists: an Internet-based survey Urology 59 2 2002 266 271 (Pubitemid 34134529)
17. P.F. Pinsky, G.L. Andriole, B.S. Kramer, R.B. Hayes, P.C. Prorok, J.K. Gohagan Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial J Urol 173 3 2005 746 750 discussion 750751 (Pubitemid 40239332)
18. S.B. Zeliadt, R.M. Hoffman, R. Etzioni, V.A. Ginger, D.W. Lin What happens after an elevated PSA test: the experience of 13,591 veterans J Gen Intern Med 25 11 2010 1205 1210
19. A.A. Powell, A.A. Gravely, D.L. Ordin, J.E. Schlosser, M.R. Partin Timely follow-up of positive fecal occult blood tests strategies associated with improvement Am J Prev Med 37 2 2009 87 93
20. D.L. Miglioretti, C.M. Rutter, S.C. Bradford Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization Med Care 46 9S1 2008 S91 S96
21. R. Etzioni, K.M. Berry, J.M. Legler, P. Shaw Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 19911998 Urology 59 2 2002 251 255 (Pubitemid 34134526)
22. D. Connolly, A. Black, L.J. Murray, G. Napolitano, A. Gavin, P.F. Keane Methods of calculating prostate-specific antigen velocity Eur Urol 52 4 2007 1044 1050
23. P.A. Fishman, M.J. Goodman, M.C. Hornbrook, R.T. Meenan, D.J. Bachman, M.C. O'Keeffe Rosetti Risk adjustment using automated ambulatory pharmacy data: the RxRisk model Med Care 41 1 2003 84 99
24. L.A. McNutt, C. Wu, X. Xue, J.P. Hafner Estimating the relative risk in cohort studies and clinical trials of common outcomes Am J Epidemiol 157 10 2003 940 943 (Pubitemid 36555054)
25. A.S. Robbins, S.Y. Chao, V.P. Fonseca What's the relative risk? A method to directly estimate risk ratios in cohort studies of common outcomes Ann Epidemiol 12 7 2002 452 454
26. W.J. Catalona, D.S. Smith, D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination Enhancement of specificity with free PSA measurements JAMA 277 18 1997 1452 1455 (Pubitemid 27208887)
27. P.R. Carroll Early stage prostate cancerdo we have a problem with over-detection, overtreatment or both? J Urol 173 4 2005 1061 1062
28. A.J. Vickers, T. Wolters, C.J. Savage Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort Eur Urol 56 5 2009 753 760
29. D. Ulmert, A.M. Serio, M.F. O'Brien Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 6 2008 835 841 (Pubitemid 351398073)
30. F.H. Schroder, M.J. Roobol, T.H. van der Kwast, R. Kranse, C.H. Bangma Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49 3 2006 460 465 discussion 465 (Pubitemid 43259552)
31. R.M. Hoffman, P. Blume, F. Gilliland Prostate-specific antigen testing practices and outcomes J Gen Intern Med 13 2 1998 106 110 (Pubitemid 28092942)
32. R.L. Grubb 3rd, P.F. Pinsky, R.T. Greenlee Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial BJU Int 102 11 2008 1524 1530
33. M.T. Mandelson, E.H. Wagner, R.S. Thompson PSA screening: a public health dilemma Annu Rev Public Health 16 1995 283 306
34. K.L. Edlefsen, M.T. Mandelson, M.W. McIntosh, M.R. Andersen, E.H. Wagner, N. Urban Prostate-specific antigen for prostate cancer screening Do physician characteristics affect its use? Am J Prev Med 17 1 1999 87 90 (Pubitemid 29325062)
35. M.E. Stuart, M.A. Handley, R.S. Thompson, M. Conger, D. Timlin Clinical practice and new technology: prostate-specific antigen (PSA) HMO Pract 6 4 1992 5 11
36. J.J. Fenton, P. Franks, R.J. Reid, J.G. Elmore, L.M. Baldwin Continuity of care and cancer screening among health plan enrollees Med Care 46 1 2008 58 62
37. L.E. Ross, Y.J. Taylor, L.C. Richardson, D.L. Howard Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 20022006 J Natl Med Assoc 101 4 2009 316 324
38. H.G. Welch, L.M. Schwartz, S. Woloshin Prostate-specific antigen levels in the U.S.: implications of various definitions for abnormal J Natl Cancer Inst 97 15 2005 1132 1137 (Pubitemid 41511212)